Treatment and Diagnosis of Chronic Lymphocytic Leukemia (CLL), Breast Cancer, and Other Cancers through Use of a Monoclonal Antibody
Potential to diagnosis cancer at an earlier stage and residual disease due to the increased efficiency by detection of a single, specific marker rather than multiple nonspecific antigens. Potential cancer therapy with a reduction of side effects due to the increased specificity. Potential more effective cancer therapy due to the disruption of the receptor in the pathogenesis of the disease. Potential method for monitoring the course of a cancer therapy and for detecting minimal residual disease. Potential vehicle for the delivery of current drugs due to the specificity. Potential combination with AD-CD154 gene therapy. Features of this technology include: Monoclonal antibody reacts with ROR1 on the surface of CLL cells. ROR1 is expressed on lymphoma cells, including in CLL, small lymphocytic lymphoma, marginal cell B-Cell lymphoma, Burkett’s lymphoma, and other cancers (e.g. breast cancer), but not on normal cells. ROR1 is implicated in the pathogenesis of cancer. Humanized antibody for monoclonal antibody therapy.
The American Cancer Society reported that 10.1 million people in the U.S. have or had cancer. Moreover, another 1.4 million patients will be diagnosed this year. While there are many therapy options available, the long term survival rate for most forms of cancer is still below 40 percent. Another source estimated the total global cancer market to be worth over $42 billion i in U.S. dollars in 2005 with a growth rate of 12.6 percent. By 2010, the market is expected to surpass $60 billion in U.S. dollars. (Source: Researchmarkets.com) Of the total market, breast cancer is one of the most prevalent with 1.2 million cases in the world. The U.S. alone spends $8.1 billion dollars for the treatment of breast cancer each year. (Source: International Agency for Research on Cancer) There are approximately 300,000 cases of leukemia in the world. (Source: International Agency for Research on Cancer) CLL is the most common form of leukemia in the western world, and the number of patients who are affected is growing by 1.9 percent per year. In the U.S. alone, the CLL market was worth $153 million in 2005. (Source: The Gale Group)
This novel technology is a way to diagnose and treat CLL, breast cancer, and other cancers. A monoclonal antibody has been generated by UC San Diego against a receptor which is implicated in the progression of cancer. This protein named ROR1 is expressed on CLL B cells, but it is not present in normal lymphocytes.
Patent Number: US7091396B1
Application Number: US2001982120A
Inventor: Simon, Sanford M. | Chen, Yu
Priority Date: 17 Oct 2000
Priority Number: US7091396B1
Application Date: 17 Oct 2001
Publication Date: 15 Aug 2006
IPC Current: A01K0067027 | A01K0067033 | C12N000506 | C12N000510 | C12N001563
US Class: 800018 | 4353201 | 435325 | 435326 | 435455 | 800013
Assignee Applicant: The Rockefeller University,New York
Title: Animals, cells and methods for production of detectably-labeled antibodies
Usefulness: Animals, cells and methods for production of detectably-labeled antibodies
Summary: For producing an antigen specific detectably-labeled antibody including detectably-labeled polyclonal or monoclonal antibodies or chimeric detectably-labeled immunoglobulin useful in diagnostic and research applications for diagnosing autoimmune disease, cardiac vascular disorders, diabetes, endocrine disorders, fungal, bacterial, viral, parasitic, immunological disease, hepatic disease, etc.
Novelty: New genetically-modified mouse comprising a single vector including a fusion polynucleotide encoding an immunoglobulin component e.g. kappa light chain and at least two detectable proteins, for producing a detectably-labeled antibody
Disease Diagnostic/Treatment
Cancer/Tumor
070207510
State Of Development This technology is offered exclusively or nonexclusively in the U.S. and/or worldwide territories. A commercial sponsor for potential future research is sought. Other Information Dr. Thomas Kipps, M.D., Ph.D., is a professor of medicine, the chief of the Division of Hematology/ Oncology at the UCSD School of Medicine, and the Deputy Director of research at the Moores UC San Diego Cancer Center. He is also the director of the National CLL Research Consortium and associate director of the UC San Diego Gene Therapy Program. Related Materials Tech ID/UC Case 19549/2005-212-0 Related Cases 2005-212-0
http://cll.ucsd.edu/biographies/kipps.htm
Gene Therapy Protocol at UCSD Activates Immune System in Patients with Leukemia
USA
